- Home
- RYDE vs XBIO Comparison
RYDE vs XBIO Comparison
Compare RYDE & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- XBIO
- Stock Information
- Founded
- RYDE 2014
- XBIO N/A
- Country
- RYDE Singapore
- XBIO United States
- Employees
- RYDE N/A
- XBIO N/A
- Industry
- RYDE
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- XBIO Health Care
- Exchange
- RYDE NYSE
- XBIO Nasdaq
- Market Cap
- RYDE 5.2M
- XBIO 5.6M
- IPO Year
- RYDE 2024
- XBIO N/A
- Fundamental
- Price
- RYDE $0.37
- XBIO $3.66
- Analyst Decision
- RYDE
- XBIO Hold
- Analyst Count
- RYDE 0
- XBIO 1
- Target Price
- RYDE N/A
- XBIO N/A
- AVG Volume (30 Days)
- RYDE 1.8M
- XBIO 192.9K
- Earning Date
- RYDE 05-02-2025
- XBIO 08-12-2025
- Dividend Yield
- RYDE N/A
- XBIO N/A
- EPS Growth
- RYDE N/A
- XBIO N/A
- EPS
- RYDE N/A
- XBIO N/A
- Revenue
- RYDE $6,557,978.00
- XBIO $2,582,728.00
- Revenue This Year
- RYDE $21.13
- XBIO $10.15
- Revenue Next Year
- RYDE $13.43
- XBIO $11.11
- P/E Ratio
- RYDE N/A
- XBIO N/A
- Revenue Growth
- RYDE 3.27
- XBIO 5.63
- 52 Week Low
- RYDE $0.16
- XBIO $2.20
- 52 Week High
- RYDE $22.49
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- XBIO 52.54
- Support Level
- RYDE N/A
- XBIO $3.49
- Resistance Level
- RYDE N/A
- XBIO $3.77
- Average True Range (ATR)
- RYDE 0.00
- XBIO 0.41
- MACD
- RYDE 0.00
- XBIO -0.04
- Stochastic Oscillator
- RYDE 0.00
- XBIO 35.79
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.